Archive for the ‘Treatment’ Category

How 5 Remedies Help Reduce Inflammation – Greg Lee

https://www.linkedin.com/pulse/how-five-remedies-treatments-help-reduce-inflammation-greg-lee/

How These Five Remedies and Treatments Help Reduce Inflammation Symptoms from Lyme Disease, Parasites, and Mold

For people who suspect they have multiple infections including Lyme disease, co-infections, parasites, and mold

by Greg Lee

Fireworks have gotten more spectacular since I was a kid. At a recent Independence Day celebration, my kids and I were dazzled by an amazing display that burst forth from a single white firework shooting up into the night. Then, several yellow streamers of light slowly fell like an umbrella which whistled. Suddenly, blue, red, green, and white sparkles blossomed forth. We kept saying, “Ooooh and aaaah!” with each new spray of color.

How is a complex fireworks show similar to recurring inflammatory symptoms from unknown infections?

Just like a fireworks display shooting across the night, multiple infections can trigger bursts of unexpected symptoms

Some patients with stealthy infections like Lyme disease, mold, or parasites can have relapsing symptoms that can randomly appear and disappear. Unfortunately, these infections may not show up on blood1, saliva, or stool2 tests. Carlotta felt run down ever since she got sick with mononucleosis as a teenager. She would have occasional bouts of migrating pain, memory recall issues, and vision problems. Lab tests couldn’t identify the underlying reason for her symptoms. Multiple medical providers suggested that she go see a counselor or psychiatrist. Her symptoms would flare up during phases of her menstrual cycle, during a full moon, and in response to eating carbohydrates. Not only food but also medications made her symptoms worse.

Her flu-like symptoms would flare up when she took antibiotics

Carlotta’s symptoms increased when she took antibiotics for sinus problems. The toxic die off from drug treatment dramatically increased her flu-like symptoms of fatigue, brain fog, and misspeaking words. She felt that her immune system was producing too much inflammation in response to some unknown infection. Unfortunately, over the counter medications did little to relieve her symptoms.

Anti-inflammatory medications didn’t help much

Non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin, Advil, and Aleve took the edge off some of her flu-like symptoms. Dietary changes helped reduce symptoms however they would flare up for unknown reasons and when she ate food with wheat or sugar.

What else can help to reduce fatigue, brain fog, and flu-like symptoms from hidden infections?

Here are five multi-microbial treatments that can help with reducing symptoms from multiple types of infections

Carlotta received an electrodermal scan which detected the electrical frequencies of Lyme disease and parasitic worms in her intestines and liver. The scan also detected frequencies of mold in her sinuses. She received a combination of microparticle, aka liposomal essential oils, liposomal herbs, and treatments to help with reduce recurring symptoms from her multiple infections. These remedies have also reduced toxins and inflammatory compounds in multiple lab studies.

Multi-microbial Treatment #1: Clove bud

This herb has acrid and warm properties. In lab and animal studies, clove bud has an inhibitory effect against Vibrio cholerae, Bacillus anthracis, Salmonella typhi, Corynebacterium diptheriae, Bacillus dysenteriae, E. coli, Bacillus subtilis, Staphlococcus aureus3, Methicillin-resistant Staphylococcus aureus (MRSA)4, Enterococcus faecalis5, Staphylococcus epidermidis, Streptococcus pyogenes, and Pseudomonas aeruginosa6. Biflorin, a compound in clove buds, protected against bacterial endotoxins, and inflammatory compounds tumor necrosis factor-α (TNF-α) and interleukin (IL-6) in a mouse study7. This herb has also been recommended for the treatment of worms and parasites in humans8.

In Chinese medicine, it is used to warm the abdomen and relieve pain. Clove is also used to treat hiccups, nausea, morning sickness, vomiting, and diarrhea. This herb is also used to treat impotence, and coldness in the body and extremities. It also promotes digestion by increasing bile and gastric acid secretions. Clove is also used topically to treat toothache. The essential oil has anti-asthmatic properties.

Essential oil of clove contains these compounds: eugenol, caryophyllene, acetyleugenol, α- caryophyllene, and chavicol. In lab research, clove essential oil completely dissolves the borrelia biofilm and kills the drug persistent spirochete form of the Lyme9. In another study, clove essential oil inhibits Candida, Aspergillus, and some dematophytes including fluconazole resistant strains10. In another study, the compound eugenol was effective at inhibiting different fungi including Fusarium moniliforme, Fusarium oxysporum, Aspergillus species, Mucor species, Trichophyton rubrum and Microsporum gypseum11. In a third study, clove essential oil increased the effectiveness of fluconazole and voriconazole against multiple Candida species12. In another study, this essential oil was effective at inhibiting drug resistant Candida biofilms13. Low internal doses of clove essential oil have been used safely and effectively for years with patients diagnosed with Lyme disease, parasites, and mold toxicity. This herb is contraindicated in cases of fever and excess internal heat accompanied with symptoms of dryness. Side effects of this herb include dizziness, palpitations, chest oppression, headache, perspiration, decreased blood pressure, and skin rash. In addition to clove, cinnamon can be effective against many different microbes and parasites.

Multi-microbial Treatment#2: Cinnamon bark

The properties of this herb are acrid, sweet, and hot. Cinnamon has an inhibitory effect on dermatophytes, pathogenic fungi, and many gram positive bacteria14. In a lab study, cinnamon compounds inhibited the malaria parasite15. These compounds are succinic acid, glutathione, L-aspartic acid, beta-alanine, and 2-methylbutyryl glycine. Given the similarity between malaria and Babesia, this herb may be effective against this co-infection. Another compound, cinnamaldehyde, has inhibits parasitic worms in a lab study16. Cinnamon was also effective at reducing parasitic cysts of Giardia in a rat study.17

This herb also contains the following active compounds: cinnamic aldehyde, cinnamic acid, cinnamyl acetate, phenylpropyl acetate, cinncassiol-A, -B, -C1, -C2, -C3, cinnzelanine, and cinnzeylanol.

This herb is used in Chinese medicine to treat a wide variety of disorders including intolerance to cold, cold extremities, weakness, soreness and coldness of the low back and knees, impotence, lack of libido, excess urine production, and loose stools. It is also used to treat wheezing, asthma, labored breathing, swelling, and profuse phlegm. Cinnamon is also used for dizziness, flushed face, sore throat, and coldness in the lower extremities. This herb also treats epigastric and abdominal pain, vomiting, diarrhea, gas, bloating, slow digestion, hernia pain, and spasmodic pain in the stomach and intestines. It is also used to treat hypercoagulation, irregular menstruation, amenorrhea, dysmenorrhea, postpartum pain, external injuries, trauma, deep rooted sores, psoriasis, and feelings of oppression in the abdomen.

Cinnamon is contraindicated during pregnancy and in patients with signs of excess heat, excess dryness, and excess bleeding. Excess amount of cinnamon can result in symptoms of flushed face, red eyes, dry mouth and tongue, bleeding, nausea, vomiting, abdominal pain, excess urination, anuria, burning sensations upon urination, excess serum proteins in the urine, dizziness, blurred vision, and numbness of the tongue.

Intravenous cinnamon reduced blood pressure, decreased heart rate, peripheral vasodilation, and decreased vessel resistance within 3-5 minutes. Subcutaneous injection of cinnamon in dogs increased the white blood cell count by 150 – 200%. In a rat study, essential oil of cinnamon has an analgesic and sedative effect.

In lab research, cinnamon bark essential oil completely eradicates the Lyme disease biofilm and the drug persistent spirochete form18. Cinnamon bark essential oil was effective at inhibiting Aspergillus and Penicillium mold species19. This essential oil inhibits Aspergillus species and aflatoxin, aflatoxin-B1, and aflatoxin-G1 production. These toxins are inhibited because the essential oil binds to the DNA of aflatoxins. Also, this essential oil reacts with reactive oxygen species produced by aflatoxins, which has a protective effect on cells20. In another study, cinnamon bark essential oil was the most effective against oral isolates of Candida albicans21. Another study demonstrated that cinnamon bark essential oil was effective against fluconazole susceptible Candida species22. Liposomal cinnamon oil was effective at inhibiting MRSA and it’s biofilms in a lab study23. Low dilutions of liposomal cinnamon essential oil have been taken internally by people diagnosed with multiple infections safely without reported side-effects. In addition to cinnamon, artemisia has antimicrobial effects against many pathogens.

Multi-microbial Treatment#3: Artemisia

Artemisia and its derivative compounds, artemisinin, liposomal artemisinin, and artesenuate, are being used by physicians to fight Babesia24 infections. Artemisinin has been used effectively with other anti-protozoa medications to cure relapsing Babesia. Artemisinin has also been effective in multiple studies against cytomegalovirus, Toxoplasma gondii (protozoa), Schistosoma species and Fasciola hepatica (worms) and Cryptococcus neoformans (fungi)25.

Artemisia is recommended for treating leptospirosis and Lyme disease in Chinese medicine26. Artemisia annua is also effective in inhibiting Staphylococcus aureus (staph), Bacillus anthracis (anthrax), Corynebacterium diphtheriae (diphtheria), Pseudomonas aeruginosa, Bacillus dysenteriae (dysentery), and Mycobacterium tuberculosis (tuberculosis)27. Using the whole herb instead of a derivative compound increases the benefits by including other active compounds. Multiple sesquiterpene and flavonoid compounds from Artemisia annua neutralized the effects of bacterial toxins in a lab study28. Artemisia annua contains rosmarinic acid which demonstrated a synergistic interaction with artemisinin against the malaria protozoa in a lab study29. This herb and it’s compound artemisinin inhibited the production of bacterial endotoxins and the inflammatory cytokine TNF-α in a rat study30.

Artemisia annua has the properties of clears heat, treats malaria, cools the blood, clears liver heat, and brightens the eyes. It is also used to treat “steaming bone disorder” or the feeling that one’s bones are being cooked, tidal fever, unremitting low-grade fever, thirst, soreness and weakness of the low back and knees, irritability, and heat in the palms, soles, and the middle of the chest. Other symptoms this herb is used to treat are warmth at night and chills in the morning, absence of perspiration, heavy limbs, stifling sensation in the chest, and a flushed face. This herb also treats red eyes, dizziness, photophobia, arrhythmia, and jaundice.

This herb is cautioned in patients with diarrhea and coldness in the stomach. Azole antifungals and calcium channel blockers may present significant herb-drug interactions with this herb. In long term studies, this herb had no adverse effects on vital organs31. In addition to artemisia, silver nanoparticles have multiple anti-microbial properties.

Multi-microbial Treatment#4: Silver Nanoparticles

Silver nanoparticles have been used safely and effectively to inhibit many drug resistant and biofilm forming bacteria and fungi including Streptococcus mutans32, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa33, Escherichia coli34, and Enterococcus faecalis35 in lab studies. Silver particles are also effective at inhibiting multiple species of pathogenic fungi and their toxins in lab studies36. This form of silver has also been effective against multiple protozoa including Entamoeba histolytica, Cryptosporidium parvum, and Plasmodium falciparum (malaria)37. In water studies, silver has also been effective at reducing the amount of helminth (worm) eggs in waste water38.

When in combination with cinnamon bark, silver inhibits H7N3 influenza A virus a lab experiment39. When combined with tea tree essential oil in a microparticle liposome, silver greatly enhances the antimicrobial and anti-toxin properties against Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans40. In addition to silver, Microcurrent offers a highly flexible and targeted treatment for inhibiting pathogens, toxins, and resulting inflammation.

Multi-microbial Treatment#5: Frequency Specific Microcurrent

Frequency Specific Microcurrent (FSM) is amazingly targeted and customizable form of electrical frequency treatment for chronic infections. Carlotta received anti-microbial, anti-toxin, anti-inflammatory frequencies directed into her sinuses, liver, intestines, and memory regions of the brain. Frequencies were also applied to neutralize mold toxins, inhibit spirochetes, fungi, protozoa, bacteria, parasites, and reduce brain and intestinal inflammation. She also received frequencies for increasing adrenal energy, disrupting biofilms in her sinuses, and zapping intracellular infections. With each microcurrent treatment, she felt less toxic and less inflamed, more energetic, and was able to find and speak words with greater clarity. Multiple remedies and treatment may be effective at reducing symptoms from Lyme, parasites and mold, toxins, and resulting inflammation.

Using multiple treatments, patients report faster improvements in their chronic inflammation symptoms

Similar to a dazzling multi-stage fireworks display, the proper combination of treatments and liposomal remedies may give your immune system a burst of support to fight multiple types of infections including Lyme disease, parasites and mold. These treatments may also help to neutralize toxins and lower inflammation. For the first time in years, Carlotta looked forward to going to her kid’s sporting events with an abundance of energy. She remembered her family’s activity schedule without having to look at a calendar. She restarted movement classes since her migrating pains had ceased. Since liposomal remedies require specific training on their formulation and come with cautions on their use, work with a Lyme literate natural practitioner to develop a safe and effective strategy for addressing symptoms from multiple infections.

– Greg

P.S. Do you have experiences where treatment or remedies helped you reduce symptoms from multiple infections? Tell us about it in a comment below.

================================================================

  1. “Lyme Disease Is a Clinical Diagnosis, Based on Your Medical History, Symptoms and Exposure to Ticks.” LymeDisease.org. Accessed July 7, 2017.
  2. Klinghardt, D. A Deep Look Beyond Lyme. 2012 Physician’s Round Table. January 28th, 2012. Tampa, FL.
  3. Chen, John K., and Tina T. Chen. 2004. Chinese Medical Herbology and Pharmacology. City of Industry CA: Art of Medicine Press, Inc., p. 461 – 462.
  4. Warnke, Patrick H., Stephan T. Becker, Rainer Podschun, Sureshan Sivananthan, Ingo N. Springer, Paul A. J. Russo, Joerg Wiltfang, Helmut Fickenscher, and Eugene Sherry. “The Battle against Multi-Resistant Strains: Renaissance of Antimicrobial Essential Oils as a Promising Force to Fight Hospital-Acquired Infections.” Journal of Cranio-Maxillo-Facial Surgery: Official Publication of the European Association for Cranio-Maxillo-Facial Surgery 37, no. 7 (October 2009): 392–97. doi:10.1016/j.jcms.2009.03.017.
  5. Rahman, Muntasir, Md Mahbubur Rahman, Suzan Chandra Deb, Md Shahanoor Alam, Md Jahangir Alam, and Md Tofazzal Islam. “Molecular Identification of Multiple Antibiotic Resistant Fish Pathogenic Enterococcus Faecalis and Their Control by Medicinal Herbs.” Scientific Reports 7, no. 1 (June 16, 2017): 3747. doi:10.1038/s41598-017-03673-1.
  6. Ali, Nafisa Hassan, Shaheen Faizi, and Shahana Urooj Kazmi. “Antibacterial Activity in Spices and Local Medicinal Plants against Clinical Isolates of Karachi, Pakistan.” Pharmaceutical Biology 49, no. 8 (August 2011): 833–39. doi:10.3109/13880209.2010.551136.
  7. Lee, Hwi-Ho, Ji-Sun Shin, Woo-Seok Lee, Byeol Ryu, Dae Sik Jang, and Kyung-Tae Lee. “Biflorin, Isolated from the Flower Buds of Syzygium Aromaticum L., Suppresses LPS-Induced Inflammatory Mediators via STAT1 Inactivation in Macrophages and Protects Mice from Endotoxin Shock.” Journal of Natural Products 79, no. 4 (April 22, 2016): 711–20. doi:10.1021/acs.jnatprod.5b00609.
  8. Clark, Hulda Regehr. The Cure for All Diseases: With Many Case Histories. 1st edition. San Diego: New Century Press, 1995. p. 341.
  9. Feng, Jie, Shuo Zhang, Wanliang Shi, Nevena Zubcevik, Judith Miklossy, and Ying Zhang. “Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia Burgdorferi.” Frontiers in Medicine 4 (October 11, 2017).
  10. Pinto E, Vale-Silva L, Cavaleiro C, Salgueiro L. Antifungal activity of the clove essential oil from Syzygium aromaticum on Candida, Aspergillus and dermatophyte species. J Med Microbiol. 2009 Nov;58(Pt 11):1454-62. Epub 2009 Jul 9.
  11. Inder Singh Rana, A. S. Rana, R. C. Rajak. Evaluation of antifungal activity in essential oil of the Syzygium aromaticum (L.) by extraction, purification and analysis of its main component eugenol. Brazilian Journal of Microbiology (2011) 42: 1269-1277 ISSN 1517-8382
  12. Rózalska B, Sadowska B, Wieckowska-Szakiel M, Budzyńska A. [The synergism of antifungals and essential oils against Candida spp. evaluated by a modified gradient-diffusion method]. Med Dosw Mikrobiol. 2011;63(2):163-9.
  13. Khan MS, Ahmad I. Biofilm inhibition by Cymbopogon citratus and Syzygium aromaticum essential oils in the strains of Candida albicans. J Ethnopharmacol. 2012 Mar 27;140(2):416-23. Epub 2012 Feb 2.
  14. Chen, John K., and Tina T. Chen. 2004. Chinese Medical Herbology and Pharmacology. City of Industry CA: Art of Medicine Press, Inc., p. 447 – 449.
  15. Parvazi, Shirin, Sedigheh Sadeghi, Mehri Azadi, Maryam Mohammadi, Mohammad Arjmand, Farideh Vahabi, Somye Sadeghzadeh, and Zahra Zamani. “The Effect of Aqueous Extract of Cinnamon on the Metabolome of Plasmodium Falciparum Using 1HNMR Spectroscopy.” Journal of Tropical Medicine 2016 (2016). doi:10.1155/2016/3174841.
  16. Williams, Andrew R., Aina Ramsay, Tina V. A. Hansen, Honorata M. Ropiak, Helena Mejer, Peter Nejsum, Irene Mueller-Harvey, and Stig M. Thamsborg. “Anthelmintic Activity of Trans-Cinnamaldehyde and A- and B-Type Proanthocyanidins Derived from Cinnamon (Cinnamomum Verum).” Scientific Reports 5 (September 30, 2015). doi:10.1038/srep14791.
  17. Mahmoud, Abeer, Rasha ATTIA, Safaa SAID, and Zedan IBRAHEIM. “Ginger and Cinnamon: Can This Household Remedy Treat Giardiasis? Parasitological and Histopathological Studies.” Iranian Journal of Parasitology 9, no. 4 (2014): 530–40.
  18. Feng, Jie, Shuo Zhang, Wanliang Shi, Nevena Zubcevik, Judith Miklossy, and Ying Zhang. “Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia Burgdorferi.” Frontiers in Medicine 4 (October 11, 2017).
  19. Singh G, Maurya S, DeLampasona MP, Catalan CA. A comparison of chemical, antioxidant and antimicrobial studies of cinnamon leaf and bark volatile oils, oleoresins and their constituents. Food Chem Toxicol. 2007 Sep;45(9):1650-61. Epub 2007 Feb 28.
  20. Lokman Alpsoy. Inhibitory Effect of Essential Oil on Aflatoxin Activity. African Journal of Biotechnology Vol. 9(17), pp. 2474-2481, 19 April, 2010
  21. Carvalhinho S, Costa AM, Coelho AC, Martins E, Sampaio A. Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses. Mycopathologia. 2012 Jul;174(1):69-76. Epub 2012 Jan 14.
  22. Pozzatti P, Scheid LA, Spader TB, Atayde ML, Santurio JM, Alves SH. In vitro activity of essential oils extracted from plants used as spices against fluconazole-resistant and fluconazole-susceptible Candida spp. Can J Microbiol. 2008 Nov;54(11):950-6.
  23. Cui, Haiying, Wei Li, Changzhu Li, Saritporn Vittayapadung, and Lin Lin. “Liposome Containing Cinnamon Oil with Antibacterial Activity against Methicillin-Resistant Staphylococcus Aureus Biofilm.” Biofouling 32, no. 2 (2016): 215–25. doi:10.1080/08927014.2015.1134516.
  24. Krause, Peter. Panel: Genetic and Acquired Determinants of Host Susceptibility and Vulnerable Populations at the Institute of Medicine of the National Academy of Sciences: A Workshop on the Critical Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of Lyme and Other Tick-borne Diseases: the Short-Term and Long-Term Outcomes. Washington, DC. October 11, 2010
  25. Ho, Wanxing Eugene, Hong Yong Peh, Tze Khee Chan, and W. S. Fred Wong. “Artemisinins: Pharmacological Actions beyond Anti-Malarial.” Pharmacology & Therapeutics 142, no. 1 (April 2014): 126–39. doi:10.1016/j.pharmthera.2013.12.001.
  26. Dharmananda, S. Lyme Disease: Treatment with Chinese Herbs
  27. Chen, John K., and Tina T. Chen. 2004. Chinese Medical Herbology and Pharmacology. City of Industry CA: Art of Medicine Press, Inc., pp. 244-246
  28. Zhu, Xiaoxin X., Lan Yang, Yujie J. Li, Dong Zhang, Ying Chen, Petra Kostecká, Eva Kmoníčková, and Zdeněk Zídek. “Effects of Sesquiterpene, Flavonoid and Coumarin Types of Compounds from Artemisia Annua L. on Production of Mediators of Angiogenesis.” Pharmacological Reports: PR 65, no. 2 (2013): 410–20.
  29. Suberu, John O., Alexander P. Gorka, Lauren Jacobs, Paul D. Roepe, Neil Sullivan, Guy C. Barker, and Alexei A. Lapkin. “Anti-Plasmodial Polyvalent Interactions in Artemisia Annua L. Aqueous Extract–Possible Synergistic and Resistance Mechanisms.” PloS One 8, no. 11 (2013): e80790. doi:10.1371/journal.pone.0080790.
  30. Tan, Y., Y. Zhao, Q. Lin, G. Xie, P. Yang, and X. Yin. “[Experimental study on antiendotoxin effect of extracts from Artemisia annua L].” Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica 24, no. 3 (March 1999): 166–71, 192.
  31. Chen, John K., and Tina T. Chen. 2004. Chinese Medical Herbology and Pharmacology. City of Industry CA: Art of Medicine Press, Inc., pp. 244-246.
  32. Pérez-Díaz, Mario Alberto, Laura Boegli, Garth James, Cristina Velasquillo, Roberto Sánchez-Sánchez, Rita-Elizabeth Martínez-Martínez, Gabriel Alejandro Martínez-Castañón, and Fidel Martinez-Gutierrez. “Silver Nanoparticles with Antimicrobial Activities against Streptococcus Mutans and Their Cytotoxic Effect.” Materials Science & Engineering. C, Materials for Biological Applications 55 (October 2015): 360–66. doi:10.1016/j.msec.2015.05.036.
  33. Yang, Jae Wook, Jae-won Choi, Sul Gee Lee, and Dong Soo Kim. “Antibacterial Properties of Artificial Eyes Containing Nano-Sized Particle Silver.” Orbit (Amsterdam, Netherlands) 30, no. 2 (March 2011): 77–81. doi:10.3109/01676830.2010.538123.
  34. Pathak, Satya P., and K. Gopal. “Evaluation of Bactericidal Efficacy of Silver Ions on Escherichia Coli for Drinking Water Disinfection.” Environmental Science and Pollution Research International 19, no. 6 (July 2012): 2285–90. doi:10.1007/s11356-011-0735-6.
  35. Wu, Daming, Wei Fan, Anil Kishen, James L. Gutmann, and Bing Fan. “Evaluation of the Antibacterial Efficacy of Silver Nanoparticles against Enterococcus Faecalis Biofilm.” Journal of Endodontics 40, no. 2 (February 2014): 285–90. doi:10.1016/j.joen.2013.08.022.
  36. Pulit, Jolanta, Marcin Banach, Renata Szczygłowska, and Mirosław Bryk. “Nanosilver against Fungi. Silver Nanoparticles as an Effective Biocidal Factor.” Acta Biochimica Polonica 60, no. 4 (2013): 795–98.
  37. “Silver Nanoparticles Treat Lyme (July 2016) Townsend Letter, Alternative Medicine Magazine.” Accessed July 7, 2017.
  38. Orta De Velásquez, M. T., I. Yáñez-Noguez, B. Jiménez-Cisneros, and V. M. Luna Pabello. “Adding Silver and Copper to Hydrogen Peroxide and Peracetic Acid in the Disinfection of an Advanced Primary Treatment Effluent.” Environmental Technology 29, no. 11 (November 2008): 1209–17. doi:10.1080/09593330802270632.
  39. Fatima, Munazza, Najam-Us-Sahar Sadaf Zaidi, Deeba Amraiz, and Farhan Afzal. “In Vitro Antiviral Activity of Cinnamomum Cassia and Its Nanoparticles Against H7N3 Influenza A Virus.” Journal of Microbiology and Biotechnology 26, no. 1 (January 2016): 151–59. doi:10.4014/jmb.1508.08024.
  40. Low, W. L., C. Martin, D. J. Hill, and M. A. Kenward. “Antimicrobial Efficacy of Liposome-Encapsulated Silver Ions and Tea Tree Oil against Pseudomonas Aeruginosa, Staphylococcus Aureus and Candida Albicans.” Letters in Applied Microbiology 57, no. 1 (July 2013): 33–39. doi:10.1111/lam.12082.

Lyme Disease Guidelines – Public Comments Accepted until August 10, 2019

https://www.lymediseaseguidelines.org/?

The Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR) 2019 Draft Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease.

Lyme Disease Guidelines: Devoted to transparency in Lyme diagnosis and treatment Guidelines

Historically, Medical Guidelines have been established by the Institute of Medicine (IOM) and posted on the National Clearing House for Guidelines website (Guidelines.gov).  Guidelines are generally written by Medical Societies and are not to be confused with Standards of Care.  They are designed to facilitate patient care, but not to dictate the care of any given patient in the Community. The Centers for Disease Control (CDC) also maintains guidelines, and these are designed for disease surveillance and public health purposes.

In 2006 the Infectious Disease Society of America (IDSA) published guidelines for Lyme Disease. In 2015 another medical society, The International Lyme and Associated Disease Society (ILADS) did the same. IDSA guidelines fell short of the IOM standards and were removed, but the ILADS guidelines remained. Currently, the ILADS guidelines are the only ones meeting IOM standards. On June 26, 2019, IDSA published a proposed set of guidelines. They are mandated to provide a 45-day period (ending August 10, 2019) for comments from the public before officially releasing them.

Go here to read IDSA guidelines and supplementary material: https://www.lymediseaseguidelines.org/guideline-links/

Go here to submit comments on guidelines: https://www.lymediseaseguidelines.org/contact-us/

Go here for “official” public comment on guidelines: https://www.surveymonkey.com/r/7HG3XCQ

For more:  https://madisonarealymesupportgroup.com/2019/07/22/idsas-insincere-request-for-guidelines-feedback/

https://madisonarealymesupportgroup.com/2019/07/09/idsa-lyme-disease-treatment-management-business-as-usual-leaves-those-with-persisting-symptoms-to-suffer-die/

https://madisonarealymesupportgroup.com/2017/08/19/dr-liegner-guidelines-used-by-managed-care-causing-lyme-deaths/

 

 

 

 

Treatment Strategies For Neuroretinitis Due to Bartonella: Current Options & Emerging Therapies

https://www.ncbi.nlm.nih.gov/pubmed/31278547/

2019 Jul 5;21(8):36. doi: 10.1007/s11940-019-0579-9.

Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies

Abstract

PURPOSE OF REVIEW:

To explore and critically appraise the published data on the current and emerging treatment modalities for neuroretinitis.

RECENT FINDINGS:

The optimum treatment strategy for neuroretinitis due to Bartonella henselae in immunocompetent individuals is not clear and a matter of debate. The role of systemic corticosteroids in infectious neuroretinitis and the optimum immunosuppressive regimen for use in recurrent idiopathic neuroretinitis also remains ill defined. There is no class 1 evidence to support a specific treatment strategy for neuroretinitis. For uncomplicated B. henselae-associated neuroretinitis in immunocompetent patients, initiation of antibiotic and corticosteroid therapy remains controversial.

  • In patients with severe vision loss and/or moderate to severe systemic symptoms, a 4- to 6-week regimen of doxycycline or azithromycin with rifampin may provide some benefit.
  • The routine use of systemic corticosteroids in infectious neuroretinitis is not recommended.
  • Targeted antimicrobial agents should be instituted in cases of neuroretinitis due to specific infectious etiologies (e.g., syphilis, Lyme disease, tuberculosis).
  • Azathioprine may be beneficial in cases of recurrent idiopathic neuroretinitis.

There is a need for collaborative, multicenter prospective studies to provide definitive guidelines regarding the use of antibiotics and corticosteroids and to evaluate future therapies in infectious and recurrent idiopathic neuroretinitis.

_________________

**Comment**

Bartonella is known to cause numerous eye issues.

https://madisonarealymesupportgroup.com/2019/04/08/case-series-bartonella-ocular-manifestations/

https://madisonarealymesupportgroup.com/2018/09/06/ocular-manifestations-of-bartonellosis/

https://madisonarealymesupportgroup.com/2017/10/23/opthalmic-manifestations-of-bartonella-infection/

https://madisonarealymesupportgroup.com/2017/07/21/bartonella-and-neuroretinitis/

https://madisonarealymesupportgroup.com/2018/07/10/bartonella-henselae-neuroretinitis-in-patients-without-cat-scratch/

https://madisonarealymesupportgroup.com/2016/01/03/bartonella-treatment/

Most Lyme literate doctors do not recommend systemic corticosteroids unless antimicrobials are used in tandem. If steroids are used alone they suppress the immune system allowing the infection(s) to worsen.

Is Disulfiram the Magic Bullet For Chronic Lyme Disease?

https://www.treatlyme.net/guide/antabuse-disulfiram-chronic-lyme-disease-treatment

Disulfiram_3D_ball

Disulfiram: Wikipedia

Please see above link for the following:

Marty Ross MD on Antabuse for Chronic Lyme Disease

This is mainly a video article. You will need to listen to the whole video for my thoughts on Antabuse (disulfiram) as a new treatment for chronic Lyme disease. Below this video I provide additional points I did not mention during Conversations with Marty Ross MD on 7/18/19 when I recorded these comments.

For more: https://madisonarealymesupportgroup.com/2019/06/03/disulfiram-in-the-treatment-of-lyme-babesiosis-3-case-reports/

https://madisonarealymesupportgroup.com/2019/07/14/disulfiram-breakthrough-drug-for-lyme-other-tick-borne-diseases/

 

FDA Approves Generic Versions of Lyrica

https://www.workerscompensation.com/news_read.php?id=33193

FDA Approves Generic Versions of Lyrica

07/25/19

Leah King



On Monday, the FDA issued a press release announcing the approval of generic versions of the drug Lyrica (pregabalin). Those of us operating in the workers compensation industry are all too familiar with Lyrica. It’s a high-priced medication utilized for the treatment of pain related to nerve damage, and its inclusion within Workers’ Compensation Medicare Set-Asides (WCMSAs) has become more common and problematic in recent years. You may recall that last October, we published a detailed blog article on the inclusion of Lyrica within WCMSAs submitted to CMS for approval. However, our concerns mounted when CMS’ published its most recent WCMSA reference guide in January, 2019, which specifically noted Lyrica as an example in the WCMSA Reference guide for off-label medication inclusion, as

Example 1: Lyrica (Pregabalin) is cited in MicroMedEx for an off-label medication use related to neuropathic pain from spinal cord injury, and a number of scientific studies indicate that Pregabalin shows statistically significant positive results for the treatment of radicular pain (a type of neuropathic pain). Spinal cord neuropathy includes injuries directly to the spinal cord or its supporting structures causing nerve impingement that results in neuropathic pain. Lyrica is considered acceptable for pricing as a treatment for WCMSAs that include diagnoses related to radiculopathy because radiculopathy is a type of neuropathy related to peripheral nerve impingement caused by injury to the supporting structures of the spinal cord.

Lyrica was initially approved by the FDA in December of 2004 for a single indication of neuropathic pain associated with diabetic peripheral neuropathy. Lyrica was developed by Pfizer, a large pharmaceutical manufacturing company. Over the course of the next fourteen years, Pfizer was successful in securing FDA approval for additional indications including fibromyalgia, neuropathic pain associated with spinal cord injury, post-herpetic neuralgia and adjunctive therapy for adult patients with partial onset seizures. In addition, Lyrica has seemed to gain medical acceptance for the treatment of low back pain and radiculopathy in an off-label capacity, hence the inclusion of this medication in many CMS approved WCMSAs, as we mentioned in our earlier blogs. Pfizer’s patent protection for Lyrica was scheduled to expire in December of 2018. However, in November of 2018, Pfizer secured a six-month patent extension for a new pediatric indication of Lyrica. At that time, there was a collective sigh of disappointment, because news of the patent extension meant that a generic version of Lyrica would be delayed.

In Monday’s press release, the FDA announced that it had approved generic drug applications for pregabalin submitted by eight manufacturers: Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals and Teva Pharmaceuticals. The multitude of manufacturers who are entering the market at this early stage could have significant implications for the price of pregabalin in the coming months. A common regulatory scenario for generic drugs is that the first generic manufacturer to secure FDA approval of a generic drug application will receive a 180-day period of marketing exclusivity. During this 180-day period of exclusivity, other generic manufacturers are precluded from entering the market. The potential for six months of exclusive generic drug marketing was incorporated into the Hatch-Waxman Amendments in 1984 with the best of intentions. The exclusivity period was established to stimulate the development of generic medications in an effort to lower drug costs. In more recent years, however, the award of exclusivity to a generic manufacturer has come under fire because exclusivity can have the unintended result of delaying the entrance of the generic product into the market. Generic manufacturers sometimes enter into reverse payment arrangements with the brand name manufacturer, whereby the generic manufacturer accepts payment from the brand name manufacturer in exchange for an agreement to delay the production of the generic product for a certain length of time. In the pharmaceutical industry, these agreements are known as “pay-to-delay” or “pay-for-delay” arrangements.

In the case of pregabalin, the FDA did not grant a period of generic exclusivity to a single manufacturer. This will likely produce favorable market conditions over the next few months, as these eight manufacturers will begin to distribute the generic pregabalin products. With several manufacturers entering the market sooner rather than later, the increased competition for market share will likely result in price decreases over the course of the next several months. Of course, we’ll continue to monitor the average wholesale price (AWP) of pregabalin products and post noteworthy developments here on our blog. Pregabalin will be available in generic formulations of all commercially available formulations of Lyrica: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg capsules. It will also be available as a 20mg per ml oral solution.

By Leah King

Courtesy of MedVal